factual
Genome-engineering spinoffs as primary business value
Colossal's primary business driver is spinning out genome-engineering technology companies—two already spun off, two more in process—which Lamm believes are worth tens of billions of dollars because no one else has matched their capabilities, validated by feedback from healthcare investors like In-Q-Tel.
factualpending
Speaker
Ben LammEvidence Quote
“Just our genome engineering technologies, we think, are worth tens of billions of dollars”
Created: 6/14/2026, 1:46:37 AM
Your notes
Loading notes...